<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Restrictive cardiomyopathies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Restrictive cardiomyopathies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Restrictive cardiomyopathies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Naser M Ammash, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Restrictive cardiomyopathy (RCM) is a broad classification of heart disease characterized by the predominance of severe diastolic dysfunction, normal or mildly increased ventricular wall thickness, and either normal or mildly reduced ejection fraction. RCM may be idiopathic, toxic, or caused by genetic, infiltrative, inflammatory, or other disorders.</p><p>This topic covers the clinical presentation, diagnostic evaluation, treatment, and prognosis of patients with RCM. The classification of cardiomyopathies and the diagnosis and treatment of other forms of diastolic heart failure (HF; eg, HF with preserved ejection fraction) are discussed separately. (See  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p class="headingAnchor" id="H16050011"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>RCM is a rare form of cardiomyopathy [<a href="#rid1">1,2</a>]. The prevalence of RCM and the incidence of RCM among persons with causative diseases or exposures are unclear due to difficulties with proper classification and reporting [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3979774716"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>RCMs are caused by a broad range of diseases (most commonly amyloidosis and sarcoidosis), medical therapies (eg, radiation therapy), and genetic mutations [<a href="#rid4">4</a>]. Patients without an identifiable cause are considered to have idiopathic RCM.</p><p>Grouping the etiologies of RCMs is difficult given the imperfect separation between the origin of causative diseases and mechanisms of myocardial injury (eg, storage diseases have a genetic origin, but cause myocardial injury via infiltration). The following categories focus on the primary mechanism of injury to the myocardium:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infiltrative disorders</strong> – RCM can be caused by infiltration of the myocardium by protein (eg, amyloid), iron, eosinophils, carbohydrate, fat, metabolic products (eg, cystine), and tumors [<a href="#rid5">5-9</a>]. Among adults, two representative disorders causing infiltrative RCM are cardiac amyloidosis and, less commonly, hemochromatosis [<a href="#rid3">3</a>]. In rare cases, RCM can be caused by diseases that result in eosinophilic infiltration of the myocardium (eg, hypersensitivity myocarditis, endomyocardial fibrosis) [<a href="#rid8">8</a>]. RCM can also be caused by an inborn error of metabolism that results in myocardial infiltration by carbohydrate (eg, mucopolysaccharide) or fat (eg, sphingolipid); such patients typically present during childhood, although a metabolic evaluation in young adults may reveal the diagnosis [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Cardiac iron overload'</a> and  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory disorders </strong>– Cardiac sarcoidosis can present as an RCM or as a dilated cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-related cardiotoxicity</strong> – RCM is commonly caused by a variety of medical treatments, with the most common being mediastinal radiation. Radiation therapy for breast cancer, Hodgkin lymphoma, and other chest malignancies may damage cardiac structures, causing fibrosis of the myocardium and resulting in an RCM, sometimes many years after initial treatment [<a href="#rid10">10-13</a>]. The extent of radiation injury depends upon the strength of radiation and the response of the affected structures. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a> and  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a>, commonly used to treat autoimmune disorders, can cause RCM, and reports of hydroxychloroquine-induced cardiomyopathy suggest an average length of use of 13 years and average cumulative dose over 1800 g among those affected [<a href="#rid14">14-17</a>]. Anthracyclines have been reported to cause RCM; however, concomitant treatment with radiation in patients receiving anthracyclines may have confounded this association [<a href="#rid18">18-24</a>]. Other drugs that may cause RCM include methysergide, serotonin analogs, ergotamines, mercurial agents, and <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> [<a href="#rid25">25-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes </strong>– Gene variants represent an important cause of RCM, and variants in genes encoding myosin, troponin, titin, actin, lamin, desmoplakin, desmin, BAG cochaperone 3, and filamin C have all been associated with RCM phenotypes [<a href="#rid29">29-32</a>]. Many of the gene variants known to cause RCM overlap with gene variants that cause hypertrophic cardiomyopathy. (See <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes </strong>– Scleroderma, Noonan syndrome, and Werner syndrome are rare or uncertain causes of RCM [<a href="#rid33">33-37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic </strong>– RCM is considered idiopathic if no underlying etiology can be identified after a comprehensive diagnostic evaluation. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p></p><p class="headingAnchor" id="H3925361433"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H647173518"><span class="h2">Clinical presentations</span><span class="headingEndMark"> — </span>Most patients with RCM present with signs and symptoms of HF (eg, dyspnea with exertion, edema) progressing over months or years. Some patients may present earlier in the course of the disease with a subtle decrease in exercise tolerance, whereas others may present later with more severe symptoms and signs of end-organ dysfunction. Some patients may present with atrial fibrillation (AF) as the first manifestation [<a href="#rid38">38</a>]. Occasionally, patients with mixed restrictive-constrictive disease may present with persistent HF due to RCM following pericardiectomy for treatment of constrictive pericardial disease. (See  <a class="medical medical_review" href="/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis", section on 'Treatment of late (chronic) disease'</a>.)</p><p>While most patients with RCM will present as described above, patients with RCM associated with amyloidosis or sarcoidosis have complex and distinctive presentations that include cardiac and extracardiac features:</p><p class="bulletIndent1"><span class="glyph">●</span>Amyloidosis may present with HF, syncope, AF, and, rarely, sudden death [<a href="#rid39">39,40</a>]. Extracardiac manifestations of amyloidosis include kidney function impairment, proteinuria, peripheral neuropathy, carpal tunnel syndrome, and gastrointestinal symptoms (eg, malabsorption). (See  <a class="medical medical_review" href="/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"</a> and  <a class="medical medical_review" href="/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical features of sarcoidosis vary according to the organ system that is predominantly affected. Cardiac manifestations of sarcoidosis include chest pain, HF, ventricular arrhythmias, syncope, and sudden cardiac arrest [<a href="#rid41">41</a>]. Extracardiac features of sarcoidosis include cough, cutaneous findings (eg, keloid formation), and visual changes. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Typical presentations'</a>.)</p><p></p><p class="headingAnchor" id="H416373697"><span class="h2">Examination findings</span><span class="headingEndMark"> — </span>Patients with RCM commonly present with examination findings characteristic of chronic and decompensated left- and right-sided HF (eg, hypotension, tachycardia). Signs of left-sided HF include a third heart sound (S3) and pulmonary edema. Signs of right-sided HF include elevation of the jugular venous pressure that increases with inspiration (ie, Kussmaul sign), a prominent y-descent of the jugular venous pulse, peripheral edema (sometimes severe), hepatomegaly, and ascites. In patients with end-stage RCM, signs of malnutrition (eg, cachexia, muscle wasting) or liver or kidney dysfunction (eg, jaundice, asterixis) may also be present. (See  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds"</a> and  <a class="medical medical_review" href="/d/html/1076.html" rel="external">"Examination of the jugular venous pulse"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H4114917971"><span class="h2">When to suspect RCM</span><span class="headingEndMark"> — </span>The diagnosis of RCM should be suspected in patients with symptoms and signs of HF and one or more of the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of chest irradiation</p><p class="bulletIndent1"><span class="glyph">●</span>Prior exposure to medications or drugs that are associated with RCM (eg, <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, anthracyclines)</p><p class="bulletIndent1"><span class="glyph">●</span>Family history (1<sup>st</sup> or 2<sup>nd</sup> degree relative) of RCM or hypertrophic cardiomyopathy</p><p class="bulletIndent1"><span class="glyph">●</span>History of multiple myeloma, amyloidosis, sarcoidosis, or hemochromatosis</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood eosinophilia</p><p></p><p class="headingAnchor" id="H3309507480"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>In patients who are suspected of having RCM, the initial evaluation focuses on differentiating RCM from other cardiomyopathies and evaluating for potential secondary causes. All patients should have a focused history, echocardiography, electrocardiogram (ECG; if not already performed), chest imaging, and laboratory testing, as discussed below.</p><p class="headingAnchor" id="H3678588274"><span class="h3">History</span><span class="headingEndMark"> — </span>The initial evaluation of the patient suspected of having RCM begins with a thorough history focused on identifying risk factors, family history, or diseases associated with RCM (see <a class="local">'Etiology'</a> above). We assess for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>History of mediastinal radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of prior exposure to <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of sarcoidosis, amyloidosis, hemochromatosis, or inborn error metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history (1<sup>st</sup> or 2<sup>nd</sup> degree relative) of RCM, HF, hypertrophic cardiomyopathy, arrhythmias, sudden cardiac arrest, amyloidosis, or heart transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family member with a known pathologic gene variant associated with RCM. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="headingAnchor" id="H3439006824"><span class="h3">Echocardiography</span><span class="headingEndMark"> — </span>All patients suspected of RCM should undergo echocardiography to demonstrate the characteristic pattern of findings that define RCM and to exclude or identify other causes of HF (eg, dilated cardiomyopathy, valvular heart disease, pericardial disease, or pulmonary hypertension). While there is no formal echocardiographic definition of RCM, the signs that characterize RCM include the following  (<a class="graphic graphic_diagnosticimage graphicRef69180" href="/d/graphic/69180.html" rel="external">image 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Normal or near normal left ventricular (LV) systolic function and cavity size</p><p class="bulletIndent1"><span class="glyph">●</span>Marked enlargement of one or both atria</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal diastolic function</p><p></p><p>In the presence of clinical HF, this pattern of echocardiographic signs warrants further testing for specific causes of RCM. Severe diastolic dysfunction alone (eg, restrictive filling, low mitral annular E’ velocity) does not confirm the presence of RCM and is commonly present in many forms of severely decompensated HF  (<a class="graphic graphic_figure graphicRef72146" href="/d/graphic/72146.html" rel="external">figure 1</a>).</p><p>Once the characteristic pattern of RCM is identified, the echocardiogram should be reviewed for features that may help identify a specific etiology of RCM. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac amyloidosis (all forms) </strong>– In cardiac amyloidosis, the left and right ventricular walls are often mildly and symmetrically thickened, the myocardium may have a granular appearance, and myocardial strain imaging may show preserved apical function  (<a class="graphic graphic_diagnosticimage graphicRef131873" href="/d/graphic/131873.html" rel="external">image 2</a>). However, these signs neither confirm nor exclude cardiac amyloidosis, and further testing is required to confirm the diagnosis [<a href="#rid42">42</a>]. (See <a class="local">'Approach to additional testing'</a> below and  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation-induced RCM </strong>– In radiation-induced RCM, the echocardiogram reveals structural abnormalities within the field of radiation, such as calcified heart valves, a thickened pericardium, or focal wall motion abnormalities (from coronary artery stenosis). (See  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac sarcoidosis</strong> – Sarcoidosis can cause global or regional (typically basal posterior and lateral) LV wall motion abnormalities. The most common finding is myocardial thinning, while less common findings include myocardial aneurysms, hypertrophy, and pericardial effusion. Additional cardiac and noncardiac testing for sarcoidosis is required to confirm the diagnosis. (See <a class="local">'Approach to additional testing'</a> below and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypereosinophilic syndrome </strong>– In eosinophilic myocarditis or hypereosinophilic syndrome, the echocardiogram is often unrevealing during the initial necrotic stage of eosinophilic endocardial and myocardial infiltration. In the thrombotic stage of the disease, the damaged endocardium may have associated thrombus, predominantly at the ventricular apices. During the subsequent fibrotic stage, increased endomyocardial echogenicity is seen affecting one or both ventricles, sometimes with overlying thrombus; in addition, ventricular filling is restricted, and atrioventricular valve leaflets may be tethered. (See  <a class="medical medical_review" href="/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Cardiac disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endomyocardial fibrosis </strong>– Endomyocardial fibrosis may be a form of eosinophilic cardiomyopathy and is characterized by LV, right ventricular, or biventricular apical fibrosis. Specific diagnostic criteria for endomyocardial fibrosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4927.html" rel="external">"Endomyocardial fibrosis"</a>.)</p><p></p><p>Echocardiography is also helpful in differentiating RCM from constrictive pericarditis. (See  <a class="medical medical_review" href="/d/html/4946.html" rel="external">"Differentiating constrictive pericarditis and restrictive cardiomyopathy", section on 'Noninvasive testing'</a>.) </p><p class="headingAnchor" id="H3875860391"><span class="h3">Electrocardiogram</span><span class="headingEndMark"> — </span>Among patients presenting with HF, the ECG may suggest specific diseases causing RCM. In general, ECG abnormalities in RCM are common and nonspecific and include atrial fibrillation (AF), premature atrial complexes, atrioventricular block, intraventricular conduction delay, LV hypertrophy, and ST-T wave abnormalities. While specific rhythms are not diagnostic of RCM, AF is common, and the presence of atrioventricular block suggests the diagnosis of either sarcoidosis or amyloidosis. Amyloidosis may present with either low voltage (60 percent of patients with light chain amyloidosis) or LV hypertrophy (30 percent of patients with wild-type transthyretin amyloidosis) [<a href="#rid43">43-45</a>]. (See  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Electrocardiogram'</a> and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis", section on 'Arrhythmias'</a>.)</p><p class="headingAnchor" id="H1941413364"><span class="h3">Chest imaging</span><span class="headingEndMark"> — </span>A chest radiograph should be obtained to determine the severity of HF. RCM generally demonstrates cardiomegaly secondary to significant atrial enlargement with or without pulmonary venous congestion and pleural effusions.</p><p>A chest radiograph may also reveal findings characteristic of a specific cause of RCM. Patients with sarcoidosis, for example, may have evidence of interstitial lung disease or mediastinal lymphadenopathy. Patients with radiation-induced RCM or those with mixed restrictive/constrictive disease may demonstrate localized pericardial calcification, which is best seen on the lateral view.</p><p class="headingAnchor" id="H2077166450"><span class="h3">Laboratory testing</span><span class="headingEndMark"> — </span>In patients with suspected RCM, we obtain the following laboratory tests to assess the severity of disease (ie, end-organ dysfunction) and to evaluate for possible secondary causes of RCM:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine and electrolytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac troponin T or I level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma B-type natriuretic peptide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron studies (serum iron, total iron-binding capacity, serum ferritin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal protein studies (serum protein electrophoresis with immunofixation and serum free light chain assay).</p><p></p><p>We do not routinely order serum angiotensin-converting enzyme levels to evaluate for the possibility of cardiac sarcoidosis, as the diagnostic utility of this test is unproven. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Proposed activity tests, including angiotensin converting enzyme (ACE) level'</a>.)</p><p>The following laboratory patterns may suggest a specific cause of RCM:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of abnormal blood counts (eg, anemia, thrombocytopenia), kidney function impairment, albuminuria, and a detectable monoclonal protein is suggestive of immunoglobulin light chain amyloidosis. (See  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A mild elevation in cardiac troponin T or I suggests the possibility of cardiac amyloidosis, but is not diagnostic. [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of polycythemia, elevated serum ferritin levels, or abnormal liver function tests is suggestive of hemochromatosis. (See  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A persistent elevation in the absolute eosinophil count may be seen in patients with eosinophilic myocarditis or endomyocardial fibrosis. (See  <a class="medical medical_review" href="/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/d/html/4927.html" rel="external">"Endomyocardial fibrosis", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H903019137"><span class="h2">Additional testing</span></p><p class="headingAnchor" id="H3112458896"><span class="h3">Approach to additional testing</span><span class="headingEndMark"> — </span>Our approach to additional diagnostic testing for a cause of RCM depends on the results of the initial evaluation (see <a class="local">'Initial evaluation'</a> above), which generally leads to one of the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>A cause of RCM is suspected </strong>- If the initial evaluation suggests one or more of the following potential causes of RCM, we take the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients suspected of cardiac amyloidosis, cardiac sarcoidosis, hereditary hemochromatosis, or hypereosinophilic syndrome, additional disease-specific testing should be performed to confirm the diagnosis or to distinguish between alternative diagnoses. (See  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/4927.html" rel="external">"Endomyocardial fibrosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients suspected of having a genetic cause of RCM (based upon a family history of RCM or HF), we obtain genetic testing. (See <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients suspected of radiation-induced toxicity, no additional testing is required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No cause of RCM is suspected </strong>– For patients in whom the initial evaluation does not identify a potential cause of RCM, a diagnosis may be suggested by cardiovascular magnetic resonance (CMR) imaging, nuclear imaging, genetic testing, and/or endomyocardial biopsy. These tests are obtained to screen for potential causes of RCM using the following step-wise approach  (<a class="graphic graphic_algorithm graphicRef132011" href="/d/graphic/132011.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In all patients in whom the initial evaluation does not identify a potential cause of RCM, we begin by obtaining CMR imaging with late gadolinium enhancement (LGE). CMR imaging can identify a broad range of imaging findings that can suggest diseases not detected by the initial evaluation. If CMR imaging identifies findings suggestive of cardiac infiltration or inflammation (such as those seen in amyloidosis or sarcoidosis), we pursue confirmatory testing for the suspected disease. If CMR imaging does not show any evidence of cardiac infiltration or inflammation, we obtain genetic testing and do not obtain additional tests for amyloidosis or sarcoidosis. (See <a class="local">'Cardiac magnetic resonance'</a> below and <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the results of CMR imaging cannot fully exclude the possibility of amyloidosis (eg, due to low-quality images or indeterminate findings) or CMR imaging cannot be performed (eg, patients with a pacemaker, patients with advanced chronic kidney disease), the choice of subsequent testing depends upon the patient’s age:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the patient is ≥50 years old, we screen for transthyretin amyloid cardiomyopathy (ATTR-CM) using bone tracer cardiac scintigraphy (eg, 99mTc-labeled pyrophosphate [PYP] scan). If the results of bone tracer cardiac scintigraphy are not consistent with cardiac amyloidosis, then we obtain genetic testing to screen for pathogenic gene variants associated with RCM. (See <a class="local">'Nuclear imaging'</a> below and <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the patient is &lt;50 years old, we obtain genetic testing to screen for pathogenic gene variants associated with RCM. (See <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If all imaging studies and genetic testing are negative, we obtain an endomyocardial biopsy (EMB) if EMB is expected to confirm or exclude a diagnosis that would change management. If all testing is negative or an EMB cannot be performed, the patient is provisionally diagnosed with idiopathic RCM. (See <a class="local">'Endomyocardial biopsy'</a> below.)</p><p></p><p class="headingAnchor" id="H1639686718"><span class="h3">Interpretation of findings</span></p><p class="headingAnchor" id="H3829157873"><span class="h4">Cardiac magnetic resonance</span><span class="headingEndMark"> — </span>In patients in whom the initial evaluation does not identify a potential cause of RCM, CMR imaging with LGE can provide additional diagnostic information that suggests diseases not detected by the initial evaluation [<a href="#rid47">47,48</a>]. (See <a class="local">'Approach to additional testing'</a> above.)</p><p>CMR imaging findings that suggest a specific cause of RCM include:</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse or subendocardial LGE of the LV, right ventricle, or atria suggest the presence of amyloidosis. CMR imaging has high sensitivity (86 percent) and specificity (92 percent) for the detection of amyloid when compared with the gold-standard of EMB [<a href="#rid49">49</a>]. If this pattern of LGE is present, cardiac deposition of transthyretin amyloid (ATTR) or light chain amyloid may be the cause of RCM, and further testing is required to confirm either diagnosis. (See <a class="local">'Nuclear imaging'</a> below and <a class="local">'Genetic testing'</a> below and  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patchy LGE in a noncoronary distribution (eg, base of the septum or base of the inferolateral wall) or basal thinning of the LV suggests cardiac sarcoidosis but is nondiagnostic and must be correlated with other data to establish the diagnosis of sarcoidosis. For many patients who undergo CMR imaging and who have findings suggestive of sarcoidosis, we obtain additional nuclear imaging (<sup>18</sup>F-fluorodeoxyglucose-positron emission tomography) to assess for the presence of active myocardial inflammation. (See  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis", section on 'Cardiovascular magnetic resonance'</a> and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis", section on 'FDG-PET'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial thickening or inflammation suggests the presence of constrictive pericarditis. If present, we pursue an evaluation to differentiate between RCM and constrictive pericarditis (ie, pericardectomy or general treatment of RCM) [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/4946.html" rel="external">"Differentiating constrictive pericarditis and restrictive cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in the cardiac T2* time suggests the presence of myocardial iron overload, which is seen in hereditary hemochromatosis or acquired iron overload syndromes. Such patients should be evaluated for hereditary hemochromatosis. (See  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Cardiac iron overload'</a> and  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'MRI'</a>.)</p><p></p><p class="headingAnchor" id="H3939614363"><span class="h4">Nuclear imaging</span><span class="headingEndMark"> — </span>In patients in whom the initial evaluation does not identify a potential cause of RCM or exclude the diagnosis of amyloidosis (eg, contraindications to CMR imaging with gadolinium, indeterminate CMR images) <strong>and</strong> who are ≥50 years old, we obtain a 99mTc-labeled PYP scan to screen for the presence of cardiac amyloid deposition. (See <a class="local">'Approach to additional testing'</a> above.)</p><p>Radiolabeled PYP localizes to sites of transthyretin amyloid deposition, and high cardiac uptake of PYP confirms the diagnosis of transthyretin cardiomyopathy (ATTR-CM). In most cases of RCM, no further testing is necessary following a positive PYP scan [<a href="#rid49">49,51</a>]. Additional information on the clinical indications and technical details of PYP scans and other bone tracer cardiac scintigraphy scans is discussed separately. (See  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Bone tracer cardiac scintigraphy'</a>.)</p><p class="headingAnchor" id="H3719294731"><span class="h4">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is performed in certain clinical settings to assess for the presence of pathologic gene variants. (See <a class="local">'Approach to additional testing'</a> above.)</p><p>Given the large number of pathologic gene variants associated with RCM, we refer patients for genetic counseling or consultation with a geneticist to help guide the selection and interpretation of genetic testing (see  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing", section on 'Basic principles'</a>). Some genetic variants known to cause RCM include variants in genes coding for transthyretin (<em>TTR</em>), sarcomeric proteins (eg, <em>TTN</em>, <em>MYH7</em>), desmosomal proteins (eg, <em>DSP</em>, <em>JUP</em>), filament proteins (eg, <em>LMNA</em>, <em>FLNC</em>), and other gene loci [<a href="#rid31">31,52-58</a>].</p><p>The interpretation of genetic testing depends upon the clinical scenario:</p><p class="bulletIndent1"><span class="glyph">●</span>In the patient with a family history of inherited cardiomyopathy and a known pathologic gene variant, positive testing for the same variant confirms the diagnosis of a genetic RCM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the patient with a family history suspicious for an inherited cardiomyopathy but without a known pathologic gene variant, positive testing for a known pathogenic gene variant or a variant of unknown significance may support the diagnosis of genetic RCM. Confirmation of the diagnosis requires expert interpretation and correlation with clinical findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the patient without a family history suspicious for an inherited cardiomyopathy, positive testing supports the diagnosis of genetic RCM. Confirmation of the diagnosis requires expert interpretation and correlation with clinical findings.</p><p></p><p class="headingAnchor" id="H1928463065"><span class="h4">Endomyocardial biopsy</span><span class="headingEndMark"> — </span>EMB is usually performed in patients in whom all imaging studies and genetic testing are negative, if a tissue sample is likely to confirm a diagnosis or exclude a diagnosis that would change clinical management.</p><p>In idiopathic RCM, light microscopic examination commonly reveals patchy endocardial and interstitial fibrosis with increased collagen deposition, myocellular hypertrophy without myofiber necrosis, or myocardial disarray. The pathologic findings of specific diseases are covered in separate topic reviews.</p><p>Other aspects of EMB are discussed separately. (See  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p class="headingAnchor" id="H4210195498"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In patients presenting with chronic HF and with echocardiographic evidence of LV hypertrophy, atrial enlargement, or severe diastolic dysfunction, the diagnosis of RCM should be differentiated from constrictive pericarditis and hypertrophic cardiomyopathy (HCM).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constrictive pericarditis</strong> – RCM and constrictive pericarditis can present with similar clinical features, including chronic severe HF, biatrial enlargement with normal systolic function, and impairment in ventricular filling. While details of the clinical history are sometimes helpful, the distinction often requires careful echocardiographic and hemodynamic assessment, pericardial imaging, and even endomyocardial biopsy. A more detailed discussion on differentiating RCM from constrictive pericarditis is presented separately. (See <a class="local">'Initial evaluation'</a> above and  <a class="medical medical_review" href="/d/html/4946.html" rel="external">"Differentiating constrictive pericarditis and restrictive cardiomyopathy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrophic cardiomyopathy</strong> – RCM and HCM can be differentiated by characteristic clinical features and imaging findings. Typically, patients with RCM present later in life, while patients with HCM present earlier (eg, young adulthood). Although patients with RCM and HCM can both present with dyspnea and fatigue, those with RCM commonly have more severe HF, and those with HCM may additionally present with chest pain, syncope, or palpitations. Echocardiography in patients with RCM often demonstrates symmetric hypertrophy of both ventricles and severe biatrial enlargement, while patients with HCM often have marked asymmetric hypertrophy of the left ventricle (eg, septal hypertrophy &gt;15 mm) with varying degrees of LV outflow tract obstruction or systolic anterior motion of the mitral valve. However, differentiating RCM from end-stage HCM can be particularly challenging if the degree of HF is severe and, in the case of HCM, the characteristic signs of HCM are absent due to cardiac remodeling. Lastly, members of the same family may present with features of RCM or HCM, which suggests that RCM and HCM can be different morphologic forms of the same sarcomeric disease [<a href="#rid59">59</a>]. The clinical manifestations and diagnosis of HCM can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no specific therapy for idiopathic RCM, whereas specific therapies may be available for certain causes of secondary RCM (eg, amyloidosis, sarcoidosis, hemochromatosis). Regardless of the etiology, the general management of patients with RCM involves management of volume status to reduce pulmonary and central venous congestion and management of end-organ (eg, liver, kidney) dysfunction. Given the progressive nature of most forms of RCM, patients should be referred early for heart transplantation.</p><p class="headingAnchor" id="H2049719865"><span class="h2">Treatment of the underlying cause</span><span class="headingEndMark"> — </span>In patients who have an underlying cause of RCM, we treat the underlying cause as appropriate. Medications associated with RCM (eg, <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>) should be discontinued. Treatment of certain underlying diseases associated with RCM (such as amyloidosis, sarcoidosis, and hemochromatosis) may increase survival, improve quality of life, and delay the need for heart transplantation. The management of these disorders is discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac amyloidosis (see  <a class="medical medical_review" href="/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac sarcoidosis (see  <a class="medical medical_review" href="/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemochromatosis (see  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a>)</p><p></p><p class="headingAnchor" id="H4210277576"><span class="h2">General management</span></p><p class="headingAnchor" id="H3882881636"><span class="h3">Volume management</span><span class="headingEndMark"> — </span>The general approach to volume management in patients with RCM is similar to that used for other forms of HF. Such an approach consists of the following components:</p><p class="bulletIndent1"><span class="glyph">●</span>The use of diuretics. (See  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of echocardiography and pulmonary artery catheterization to assess volume status. (See  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Echocardiography'</a> and  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Additional tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Referral of patients with moderate to severe HF to a chronic disease management program. (See  <a class="medical medical_review" href="/d/html/15690.html" rel="external">"Systems-based strategies to reduce hospitalizations in patients with heart failure", section on 'Outpatient strategies'</a>.)</p><p></p><p>If the patient’s volume status is difficult to manage despite optimized medical therapy (eg, multiple readmissions for volume overload, frequent and marked changes in weight complicating outpatient management), placement of an invasive hemodynamic pulmonary pressure monitor, which provides daily readings of intracardiac filling pressures, may assist with diuretic management. However, there are no data to support this approach in patients with RCM. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Device-based therapies'</a>.)</p><p class="headingAnchor" id="H2342192925"><span class="h3">Heart failure therapies</span><span class="headingEndMark"> — </span>Most of the pharmacologic and device therapies used to manage patients with other forms of HF (HF with reduced ejection fraction [HFrEF] or HF with preserved ejection fraction [HFpEF]) have not been shown to be beneficial or feasible in the management of patients with RCM. Our approach to the use of these therapies is based primarily upon <strong>our clinical experience</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span>We do <strong>not </strong>routinely administer agents that are commonly used to treat patients with HFrEF or HFpEF, such as renin-angiotensin-aldosterone system inhibitors, neprilysin inhibitors, beta blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, since there is no evidence to support their use in patients with RCM. However, such therapies may be used for the treatment of specific indications (eg, angiotensin-converting enzyme inhibitors for treatment of hypertension, beta blockers for rate control of atrial fibrillation, or SGLT-2 inhibitors for treatment of diabetes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severely decompensated RCM, we do not routinely use of intravenous vasodilator therapy (eg, <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a>, <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>) to treat refractory HF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with end-stage RCM, mechanical circulatory support (MCS) devices are a potential therapeutic option, but their efficacy in patients with RCM is not well established, and their utility is typically limited by the presence of biventricular diastolic dysfunction and end-organ dysfunction. In addition, normal or small ventricular size typically limits the feasibility of MCS device placement. The Total Artificial Heart may be used as a bridge to transplant in highly selected patients, though the efficacy of this strategy is not well described. (See  <a class="medical medical_review" href="/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices"</a> and  <a class="medical medical_review" href="/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device", section on 'Indications'</a>.)</p><p></p><p class="headingAnchor" id="H357323649"><span class="h3">Management of arrhythmias</span><span class="headingEndMark"> — </span>Patients with RCM who have atrial fibrillation should be treated similarly to patients with other forms of HF, as discussed separately. (See  <a class="medical medical_review" href="/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H495083414"><span class="h3">End-organ dysfunction</span><span class="headingEndMark"> — </span>In our experience, end-organ dysfunction is more common and less likely to be reversible in patients with RCM compared with other forms of HF. Thus, patients with RCM may require additional testing to detect and manage end-organ dysfunction. The diagnosis and treatment of syndromes commonly encountered in RCM include:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver congestion and cirrhosis. (See  <a class="medical medical_review" href="/d/html/3592.html" rel="external">"Congestive hepatopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease. (See  <a class="medical medical_review" href="/d/html/13606.html" rel="external">"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology"</a> and  <a class="medical medical_review" href="/d/html/15619.html" rel="external">"Cardiorenal syndrome: Prognosis and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension. (See  <a class="medical medical_review" href="/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2149779538"><span class="h2">Heart transplantation</span><span class="headingEndMark"> — </span>Heart transplantation may be of benefit to patients with RCM who have treatment-refractory HF symptoms and are considered to have reasonable long-term survival. Similar to all patients with advanced HF, early referral (eg, before end-organ dysfunction is severe or irreversible) may increase the likelihood of successful transplantation. Indications and contraindications for heart transplantation, including considerations specific for patients with RCM, are discussed separately. (See  <a class="medical medical_review" href="/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications", section on 'Indications for cardiac transplantation'</a> and  <a class="medical medical_review" href="/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications", section on 'Considerations for hypertrophic or restrictive cardiomyopathy'</a>.)</p><p>Patients with HF caused by RCM have the highest waitlist mortality relative to other causes of severe HF [<a href="#rid60">60-62</a>]. This may be due to end-organ dysfunction common to patients with RCM and the limited number of available therapies for severe RCM. However, despite the high waitlist mortality, patients with RCM who are successfully transplanted have reasonable, though lower, posttransplant survival relative to recipients with other HF etiologies [<a href="#rid63">63,64</a>]. As an example, in a study of 38,190 adult heart transplant recipients from the United Network of Organ Sharing (UNOS) registry, of whom 544 (1.4 percent) had RCM, 1-, 5-, and 10-year survival among patients with RCM were 84, 66, and 45 percent, respectively, compared with 85, 70, and 50 percent, respectively, for non-RCM patients. </p><p class="headingAnchor" id="H11"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Data on the prognosis of patients with RCM are limited. In patients with idiopathic RCM, the prognosis is generally poor, with most patients eventually progressing to end-stage HF. As an example, in a study of patients presenting with 94 symptomatic idiopathic RCM between 1979 and 1996, patients with RCM had worse survival compared with age- and sex-matched controls (64 versus 85 percent at five years and 37 versus 70 percent at 10 years  (<a class="graphic graphic_figure graphicRef50778" href="/d/graphic/50778.html" rel="external">figure 2</a>)) [<a href="#rid38">38</a>]. Approximately two-thirds of deaths among the patients with idiopathic RCM were cardiovascular, primarily due to HF, sudden death, arrhythmia, or a cerebrovascular accident. Among the survivors, 28, 46, and 17 percent were in New York Heart Association (NYHA) functional class I, II, and III, respectively, while 9 percent had undergone cardiac transplantation. Risk factors for mortality included male sex, age greater than 70, each increment in NYHA functional class, and left atrial diameter &gt;60 mm.</p><p>The prognosis for RCMs caused by specific diseases is also difficult to estimate due to the low prevalence of RCM. The overall prognosis and cardiovascular prognosis for diseases causing RCM, which are often not RCM-specific, are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac amyloidosis. (See  <a class="medical medical_review" href="/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac sarcoidosis. (See  <a class="medical medical_review" href="/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation-induced RCM. (See  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary hemochromatosis. (See  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="headingAnchor" id="H3340631192"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Restrictive cardiomyopathy (RCM) is a broad classification of heart disease characterized by the predominance of severe diastolic dysfunction, normal or mildly increased ventricular wall thickness, and either normal or mildly reduced ejection fraction. RCM may be idiopathic, toxic, or caused by genetic, infiltrative, inflammatory, or other disorders. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Most patients with RCM present with signs and symptoms of heart failure (HF; eg, dyspnea with exertion, edema) progressing over months or years. Some patients may present earlier in the course of the disease with a subtle decrease in exercise tolerance, whereas others may present later with more severe symptoms and signs of end-organ dysfunction. Patients with RCM associated with amyloidosis or sarcoidosis have complex and distinctive presentations that include cardiac and extracardiac features. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of RCM should be suspected in patients with symptoms and signs of HF and one or more of the following features: prior history of chest irradiation; prior exposure to medications associated with RCM (eg, <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, anthracyclines); family history (1<sup>st</sup> or 2<sup>nd</sup> degree relative) of RCM or hypertrophic cardiomyopathy; history of multiple myeloma, amyloidosis, sarcoidosis, or hemochromatosis; or peripheral blood eosinophilia. (See <a class="local">'When to suspect RCM'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who are suspected of having RCM, the initial evaluation focuses on differentiating RCM from other cardiomyopathies and evaluating for potential secondary causes. All patients should have a focused history, echocardiography, electrocardiogram (if not already performed), chest imaging, and laboratory testing. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional testing for a cause of RCM is directed by the results of the initial evaluation  (<a class="graphic graphic_algorithm graphicRef132011" href="/d/graphic/132011.html" rel="external">algorithm 1</a>). If the initial evaluation raises suspicion for a disease known to cause RCM, we follow the diagnostic evaluation for that disease. For patients in whom the initial evaluation does not identify a potential cause of RCM, a diagnosis may be suggested by cardiovascular magnetic resonance imaging, nuclear imaging, genetic testing, and/or endomyocardial biopsy. These tests are obtained to screen for potential causes of RCM using a step-wise approach. (See <a class="local">'Approach to additional testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>- There is no specific therapy for idiopathic RCM, whereas specific therapies may be available for certain causes of secondary RCM (eg, amyloidosis, sarcoidosis, hemochromatosis). Regardless of the etiology, the general management of patients with RCM involves management of volume status to reduce pulmonary and central venous congestion and management of end-organ (eg, liver, kidney) dysfunction. Given the progressive nature of most forms of RCM, patients should be referred early for heart transplantation. (See <a class="local">'Treatment of the underlying cause'</a> above and <a class="local">'General management'</a> above and <a class="local">'Heart transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H2887205200"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Daniel Jacoby, MD, and A Jamil Tajik, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McKenna WJ, Maron BJ, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circ Res 2017; 121:722.</a></li><li><a class="nounderline abstract_t">Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail 2019; 12:e005407.</a></li><li><a class="nounderline abstract_t">Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res 2017; 121:819.</a></li><li><a class="nounderline abstract_t">Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267.</a></li><li><a class="nounderline abstract_t">Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 2020; 142:e7.</a></li><li><a class="nounderline abstract_t">Dixit MP, Greifer I. Nephropathic cystinosis associated with cardiomyopathy: a 27-year clinical follow-up. BMC Nephrol 2002; 3:8.</a></li><li><a class="nounderline abstract_t">Sweet ME, Mestroni L, Taylor MRG. Genetic Infiltrative Cardiomyopathies. Heart Fail Clin 2018; 14:215.</a></li><li><a class="nounderline abstract_t">Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG. Endomyocardial fibrosis: past, present, and future. Heart Fail Rev 2020; 25:725.</a></li><li><a class="nounderline abstract_t">Navarro-Lopez F, Llorian A, Ferrer-Roca O, et al. Restrictive cardiomyopathy in pseudoxanthoma elasticum. Chest 1980; 78:113.</a></li><li><a class="nounderline abstract_t">Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011; 154:23.</a></li><li><a class="nounderline abstract_t">Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139.</a></li><li><a class="nounderline abstract_t">Avilés A, Neri N, Nambo JM, et al. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 2005; 46:1023.</a></li><li><a class="nounderline abstract_t">Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150:977.</a></li><li><a class="nounderline abstract_t">Dogar MU, Shah NN, Ishtiaq S, et al. Hydroxychloroquine-induced restrictive cardiomyopathy: a case report. Postgrad Med J 2018; 94:185.</a></li><li><a class="nounderline abstract_t">Yogasundaram H, Putko BN, Tien J, et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 2014; 30:1706.</a></li><li><a class="nounderline abstract_t">Tselios K, Gladman DD, Harvey P, et al. Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. J Clin Rheumatol 2016; 22:287.</a></li><li><a class="nounderline abstract_t">Abbasi S, Tarter L, Farzaneh-Far R, Farzaneh-Far A. Hydroxychloroquine: a treatable cause of cardiomyopathy. J Am Coll Cardiol 2012; 60:786.</a></li><li><a class="nounderline abstract_t">Gottdiener JS, Katin MJ, Borer JS, et al. Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography. N Engl J Med 1983; 308:569.</a></li><li><a class="nounderline abstract_t">Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70:519.</a></li><li><a class="nounderline abstract_t">Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73:340.</a></li><li><a class="nounderline abstract_t">Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 1986; 55:274.</a></li><li><a class="nounderline abstract_t">Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49:1486.</a></li><li><a class="nounderline abstract_t">Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109:1878.</a></li><li><a class="nounderline abstract_t">van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017; 129:2257.</a></li><li><a class="nounderline abstract_t">Mason JW, Billingham ME, Friedman JP. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 1977; 56:889.</a></li><li><a class="nounderline abstract_t">Billingham ME. Pharmacotoxic myocardial disease: an endomyocardial study. Heart Vessels Suppl 1985; 1:278.</a></li><li><a class="nounderline abstract_t">Nadeem U, Raafey M, Kim G, et al. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. Am J Clin Pathol 2021; 155:793.</a></li><li><a class="nounderline abstract_t">Muthukrishnan P, Roukoz H, Grafton G, et al. Hydroxychloroquine-induced cardiomyopathy: a case report. Circ Heart Fail 2011; 4:e7.</a></li><li><a class="nounderline abstract_t">Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of restrictive cardiomyopathy. Heart Fail Clin 2010; 6:179.</a></li><li><a class="nounderline abstract_t">Roldan-Sevilla Á, Salguero-Bodes R, Valverde-Gómez M, et al. Response by Roldan-Sevilla to Letter Regarding Article, "Missense Mutations in the FLNC Gene Causing Familial Restrictive Cardiomyopathy". Circ Genom Precis Med 2019; 12:e002622.</a></li><li><a class="nounderline abstract_t">Brodehl A, Pour Hakimi SA, Stanasiuk C, et al. Restrictive Cardiomyopathy is Caused by a Novel Homozygous Desmin (DES) Mutation p.Y122H Leading to a Severe Filament Assembly Defect. Genes (Basel) 2019; 10.</a></li><li><a class="nounderline abstract_t">Schänzer A, Rupp S, Gräf S, et al. Dysregulated autophagy in restrictive cardiomyopathy due to Pro209Leu mutation in BAG3. Mol Genet Metab 2018; 123:388.</a></li><li><a class="nounderline abstract_t">Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res 2018; 122:624.</a></li><li><a class="nounderline abstract_t">Schurle DR, Evans RW, Cohlmia JB, Lin J. Restrictive cardiomyopathy in scleroderma. J Kans Med Soc 1984; 85:49.</a></li><li><a class="nounderline abstract_t">Gelb BD, Roberts AE, Tartaglia M. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol 2015; 39:13.</a></li><li><a class="nounderline abstract_t">Cooke RA, Chambers JB, Curry PV. Noonan's cardiomyopathy: a non-hypertrophic variant. Br Heart J 1994; 71:561.</a></li><li><a class="nounderline abstract_t">Theodoropoulos TA, Bestetti RB, Fonseca PF, et al. Werner's syndrome and restrictive cardiomyopathy. Int J Cardiol 2006; 108:284.</a></li><li><a class="nounderline abstract_t">Ammash NM, Seward JB, Bailey KR, et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000; 101:2490.</a></li><li><a class="nounderline abstract_t">González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36:2585.</a></li><li><a class="nounderline abstract_t">Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. J Card Fail 2018; 24:131.</a></li><li><a class="nounderline abstract_t">Markatis E, Afthinos A, Antonakis E, Papanikolaou IC. Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med 2020; 21:321.</a></li><li><a class="nounderline abstract_t">Bellavia D, Pellikka PA, Abraham TP, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008; 101:1039.</a></li><li><a class="nounderline abstract_t">Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014; 114:1089.</a></li><li><a class="nounderline abstract_t">Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013; 18:271.</a></li><li><a class="nounderline abstract_t">González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 2017; 38:1895.</a></li><li><a class="nounderline abstract_t">Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 2018; 5:27.</a></li><li><a class="nounderline abstract_t">Li S, Wu B, Yin G, et al. MRI Characteristics, Prevalence, and Outcomes of Hypertrophic Cardiomyopathy with Restrictive Phenotype. Radiol Cardiothorac Imaging 2020; 2:e190158.</a></li><li><a class="nounderline abstract_t">Leiner T, Bogaert J, Friedrich MG, et al. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2020; 22:76.</a></li><li><a class="nounderline abstract_t">Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133:2404.</a></li><li><a class="nounderline abstract_t">Amaki M, Savino J, Ain DL, et al. Diagnostic concordance of echocardiography and cardiac magnetic resonance-based tissue tracking for differentiating constrictive pericarditis from restrictive cardiomyopathy. Circ Cardiovasc Imaging 2014; 7:819.</a></li><li><a class="nounderline abstract_t">Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail 2019; 6:1041.</a></li><li><a class="nounderline abstract_t">Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73:2872.</a></li><li><a class="nounderline abstract_t">Pereira NL, Grogan M, Dec GW. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. J Am Coll Cardiol 2018; 71:1130.</a></li><li><a class="nounderline abstract_t">Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res 2013; 113:660.</a></li><li><a class="nounderline abstract_t">Kubo T, Gimeno JR, Bahl A, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007; 49:2419.</a></li><li><a class="nounderline abstract_t">Paller MS, Martin CM, Pierpont ME. Restrictive cardiomyopathy: an unusual phenotype of a lamin A variant. ESC Heart Fail 2018; 5:724.</a></li><li><a class="nounderline abstract_t">Brodehl A, Ferrier RA, Hamilton SJ, et al. Mutations in FLNC are Associated with Familial Restrictive Cardiomyopathy. Hum Mutat 2016; 37:269.</a></li><li><a class="nounderline abstract_t">Tucker NR, McLellan MA, Hu D, et al. Novel Mutation in FLNC (Filamin C) Causes Familial Restrictive Cardiomyopathy. Circ Cardiovasc Genet 2017; 10.</a></li><li><a class="nounderline abstract_t">Vio R, Angelini A, Basso C, et al. Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Hsich EM, Rogers JG, McNamara DM, et al. Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? JACC Heart Fail 2016; 4:689.</a></li><li><a class="nounderline abstract_t">Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. J Heart Lung Transplant 2015; 34:1042.</a></li><li><a class="nounderline abstract_t">Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004; 351:859.</a></li><li><a class="nounderline abstract_t">DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant 2012; 31:1269.</a></li><li><a class="nounderline abstract_t">Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant 2018; 37:1155.</a></li></ol></div><div id="topicVersionRevision">Topic 4918 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28912179" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Classification, Epidemiology, and Global Burden of Cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170802" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28912185" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995091" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476490" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12425721" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nephropathic cystinosis associated with cardiomyopathy: a 27-year clinical follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29525649" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genetic Infiltrative Cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31414216" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endomyocardial fibrosis: past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7471831" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Restrictive cardiomyopathy in pseudoxanthoma elasticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21539537" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Review of the cardiac long-term effects of therapy for Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284266" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16019553" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16290974" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diastolic dysfunction after mediastinal irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29353247" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hydroxychloroquine-induced restrictive cardiomyopathy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25475472" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27464781" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22898072" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hydroxychloroquine: a treatable cause of cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828081" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6782873" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756067" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3456785" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608873" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17119114" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Late cardiotoxicity after treatment for Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143884" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/912852" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3870488" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacotoxic myocardial disease: an endomyocardial study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33316045" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406675" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hydroxychloroquine-induced cardiomyopathy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347786" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genetics of restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306058" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Response by Roldan-Sevilla to Letter Regarding Article, "Missense Mutations in the FLNC Gene Causing Familial Restrictive Cardiomyopathy".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31718026" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Restrictive Cardiomyopathy is Caused by a Novel Homozygous Desmin (DES) Mutation p.Y122H Leading to a Severe Filament Assembly Defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29338979" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dysregulated autophagy in restrictive cardiomyopathy due to Pro209Leu mutation in BAG3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449364" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726049" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Restrictive cardiomyopathy in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26380542" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cardiomyopathies in Noonan syndrome and the other RASopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043339" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Noonan's cardiomyopathy: a non-hypertrophic variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15916825" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Werner's syndrome and restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831523" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical profile and outcome of idiopathic restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224076" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305186" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33070538" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiac sarcoidosis: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18359328" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25212550" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23714086" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329248" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28869340" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33778596" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : MRI Characteristics, Prevalence, and Outcomes of Hypertrophic Cardiomyopathy with Restrictive Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33161900" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27143678" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25107553" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnostic concordance of echocardiography and cardiac magnetic resonance-based tissue tracking for differentiating constrictive pericarditis from restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31487121" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171094" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519355" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989711" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Genetic cardiomyopathies causing heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599605" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29741282" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Restrictive cardiomyopathy: an unusual phenotype of a lamin A variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666891" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutations in FLNC are Associated with Familial Restrictive Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29212899" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Novel Mutation in FLNC (Filamin C) Causes Familial Restrictive Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34062949" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27179836" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940074" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329423" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cardiac replacement with a total artificial heart as a bridge to transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079066" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Outcomes of adults with restrictive cardiomyopathy after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30293612" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; Focus Theme: Multiorgan Transplantation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
